Literature DB >> 17719305

Intensity of lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment among the elderly before and after the 2004 National Cholesterol Education Program Adult Treatment Panel III update.

Gregory A Nichols1, Soma Nag, Wiley Chan.   

Abstract

BACKGROUND: In 2004, the Coordinating Committee of the National Cholesterol Education Program issued an update to the Adult Treatment Panel III guidelines on cholesterol management (the Update). Our objectives were to compare the proportion of elderly patients receiving intensive or minimal-guideline lipid-lowering therapy and the proportions meeting low-density lipoprotein cholesterol (LDL-C) goals before and after the update.
METHODS: We used dispense records from Kaiser Permanente Northwest (Portland, OR) to identify elderly patients who received statin therapy in 2003 (n = 14425) and 2005 (n = 19422) and laboratory records to assess LDL-C goal attainment.
RESULTS: Among new statin initiators, 85.4% of very-high-risk patients received minimal-guideline therapy in 2005, compared with 65.3% (P < .0001) in 2003. Of all new initiators, <1% received very aggressive therapy in either year (0.4% vs 0.3%, P = .315). Overall, 77.7% and 59.0% of ongoing users in 2005 and 2003, respectively, received minimal-guideline therapy (P < .0001). Low-density lipoprotein cholesterol goal attainment did not differ between 2003 and 2005 continuing statin users. Among very-high-risk patients who initiated statin treatment, a significantly greater proportion of patients in 2005 versus 2003 attained the optional goal of <70 mg/dL (45.5% vs 34.4% P = .014). However, there was no significant difference in the proportion attaining <100 mg/dL (77.8% vs 81.8%, P = .281).
CONCLUSION: After the Update, more elderly patients were receiving intensive or minimal-guideline statin therapy. Low-density lipoprotein cholesterol goal attainment was isolated and appeared to occur by shifting already well-controlled patients to lower LDL-C levels. Although these findings may translate into less overall coronary heart disease risk, more aggressive lipid-lowering therapy would likely further reduce risk.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17719305     DOI: 10.1016/j.ahj.2007.04.037

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  6 in total

Review 1.  Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey.

Authors:  Richard Kones
Journal:  Drug Des Devel Ther       Date:  2011-06-13       Impact factor: 4.162

2.  Use of statin therapy to reduce cardiovascular risk in older patients.

Authors:  N K Wenger; S J Lewis
Journal:  Curr Gerontol Geriatr Res       Date:  2010-06-08

3.  Prevalence and overlap of different lipid abnormalities in statin-treated patients at high cardiovascular risk in clinical practice in Germany.

Authors:  Anselm K Gitt; Claus Jünger; Wenefrieda Smolka; Kurt Bestehorn
Journal:  Clin Res Cardiol       Date:  2010-06-03       Impact factor: 5.460

4.  Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US.

Authors:  Elizabeth Marrett; Changgeng Zhao; Ning Jackie Zhang; Qiaoyi Zhang; Dena R Ramey; Joanne E Tomassini; Andrew M Tershakovec; David R Neff
Journal:  Vasc Health Risk Manag       Date:  2014-04-25

5.  Low-density lipoprotein cholesterol outcomes post-non-PCSK9i lipid-lowering therapies in atherosclerotic cardiovascular disease and probable heterozygous familial hypercholesterolemia patients.

Authors:  Chi-Chang Chen; Pallavi B Rane; Dionne M Hines; Jeetvan Patel; David J Harrison; Rolin L Wade
Journal:  Ther Clin Risk Manag       Date:  2018-12-13       Impact factor: 2.423

6.  Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.

Authors:  JoAnne M Foody; Peter P Toth; Joanne E Tomassini; Shiva Sajjan; Dena R Ramey; David Neff; Andrew M Tershakovec; Henry Hu; Kaan Tunceli
Journal:  Vasc Health Risk Manag       Date:  2013-11-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.